Compare SEER & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEER | GOSS |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.3M | 97.5M |
| IPO Year | 2020 | 2018 |
| Metric | SEER | GOSS |
|---|---|---|
| Price | $2.01 | $0.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $4.19 |
| AVG Volume (30 Days) | 449.8K | ★ 18.3M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.40 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $16,578,000.00 | ★ $48,471,000.00 |
| Revenue This Year | $2.14 | N/A |
| Revenue Next Year | $25.90 | $201.64 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.99 | N/A |
| 52 Week Low | $1.55 | $0.11 |
| 52 Week High | $2.41 | $3.87 |
| Indicator | SEER | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 43.01 | 49.63 |
| Support Level | $2.00 | $0.14 |
| Resistance Level | $2.09 | $0.18 |
| Average True Range (ATR) | 0.06 | 0.02 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 4.55 | 40.79 |
Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).